Conference LibraryGated
Claim · In vivo cell engineering extends beyond T cells · CAR-T + CAR-NK + CAR-M + B-cell lanes
In vivo cell engineering via delivery platforms (LNP/mRNA · lentiviral) is no longer T-cell-only · 2025-2026 PubMed-indexed evidence shows active development across CAR-T (BCMA / CD19) · CAR-NK · CAR-Macrophage · B-cell-targeted autoimmune CAR-T (SLE) · each cell-type lane has d…
- Type
- claim
- Domain
- car-t
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_synthesis_round_8_2026-05-16
- evidence_grade
- A
- category
- in_vivo_platform_breadth_claim
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "Synthesis claim · supported by review literature · not intended to guide individual patient treatment choices · cell-type lanes at varying clinical maturity levels"
- claim_statement
- In vivo cell engineering via delivery platforms (LNP/mRNA · lentiviral) is no longer T-cell-only · 2025-2026 PubMed-indexed evidence shows active development across CAR-T (BCMA / CD19) · CAR-NK · CAR-Macrophage · B-cell-targeted autoimmune CAR-T (SLE) · each cell-type lane has di
- claim_evidence_grade
- A
- supporting_papers
- m622-b5-paper-jho-car-m-review-2026-001,m622-b5-paper-molcancer-carnk-2026-001,m622-b5-paper-natcomm-lupus-cart-2026-001,m622-b5-paper-bestpract-sle-cart-2026-001,m622-b5-paper-naturemed-esot01-001,m622-b5-paper-jcr-multivalent-lnp-2026-001,m622-b5-paper-fap-car-tlnp-2026-001
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.